Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 6, 2010, Pages 532-533

  Thannickal, Victor J ^a   Roman, Jesse ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BCR ABL PROTEIN; BOSENTAN; ETANERCEPT; IMATINIB; INTERFERON; PIRFENIDONE; PLACEBO; WARFARIN;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; EDITORIAL; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HUMAN; IDIOPATHIC DISEASE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL;

DRUG EVALUATION, PRECLINICAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS;

EID: 77749322716     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200911-1740ED     Document Type: Editorial

References (19)

1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
2. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the american thoracic society (ATS), and the european respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ers executive committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
3. de Andrade JA, Thannickal VJ. Innovative approaches to the therapy of fibrosis. Curr Opin Rheumatol 2009;21:649-655.
4. Raghu G. Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 2009; 136:330-333.
5. Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 2008;47:v10-v11.
6. Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem 2008;15:2632-2640.
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996;2:561-566.
8. Daniels CE, Lasky JE, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo controlled trial results. Am J Respir Crit Care Med 2010;181:604-610.
9. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
10. Zhuo Y, Zhang J, Laboy M, Lasky JA. Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2004;286:L182-L188.
11. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316.
12. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-1285.
13. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006;173:769-776.
14. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007;33:357-373.
15. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382.
16. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007;321:35-44.
17. Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, Standiford TJ, Thannickal VJ. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 2005;166:367-375.
18. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-5059.
19. Yoneda KY, Hardin KA, Gandara DR, Shelton DK. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer 2006;8:S31-S35.